{
    "nctId": "NCT02983214",
    "officialTitle": "Study of the Efficacy and Safety of Cilostazol in the Prevention of Ischemic Vascular Events in Diabetic Patients With Symptomatic Peripheral Artery Disease.",
    "inclusionCriteria": "* Patients aged \u226550 years with DM2 and symptomatic PAD diagnosed clinically (according to Fontaine criteria, stage IIa or IIb and III) and by measuring the \u0391\u0392\u0399.\n* Must have minimum age of 50 Years",
    "exclusionCriteria": "* Congestive heart failure, history of ventricular tachycardia, ventricular fibrillation or multifocal ventricular extrasystoles or QTc prolongation.\n* Patients with atrial fibrillation taking any anticoagulant therapy or patients with a history of cardioembolic ischemic stroke or hemorrhagic stroke.\n* Patients with a history (\u2264 12 months) of acute coronary syndrome receiving dual antiplatelet therapy, or patients receiving monotherapy with aspirin.\n* Patients with hepatic impairment (child-Pugh staging, calibration \u2265 5) or renal impairment (creatinine clearance \u2264 30ml / min), recent peptic ulcer, a history of hypersensitivity to cilostazol, cancer patients undergoing treatment."
}